The report covers forecast and analysis for the organ transplant immunosuppressant drugs market on a global and regional level. The study provides historic data from 2015 along with a forecast from 2021 to 2029 based on revenue (USD Million). The study includes drivers and restraints for the organ transplant immunosuppressant drugs market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the organ transplant immunosuppressant drugs market on a global as well as regional level.
In order to give the users of this report a comprehensive view on the organ transplant immunosuppressant drugs market, we have included a competitive landscape and analysis of Porters Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all segments are benchmarked based on their market size, growth rate and general attractiveness.
The report provides company market share analysis in order to give a broader overview of the key players in the organ transplant immunosuppressant drugs market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new drug class launch, agreements, partnerships, collaborations & joint ventures, research & development, regional expansion of major participants involved in the organ transplant immunosuppressant drugs market on global and regional basis.
The study provides a crucial view of the organ transplant immunosuppressant drugs by segmenting the market based on drug class, Transplant Type, and region. All the segments of the organ transplant immunosuppressant drugs market have been analyzed based on present and future trends and the market is estimated from 2018 to 2025.
Organ transplant refers to a medical procedure wherein the donor organ is transplanted in body of a recipient to replace a missing or damaged organ. Autograft is a transplant type wherein organs or tissues are transplanted in the same persons body. Allograft can be from cadaveric or living source and refers to a transplant between two subjects of the same species. Organ transplantation is usually done no other treatment works or in case of end state organ failure such as kidney, heart, liver failure. The immune system may attack the newly transplanted organ if the donor and recipients are not matched. Transplant rejection is quite common and the person with a transplanted organ has to take immunosuppressant drugs for a lifetime.
The demand for organ transplant immunosuppressant drugs market is driven by growing demand for transplantation, increasing investment for research and development in tissue engineering, technological advancements in organ transplants. Increasing chronic disease burden is another factor that is contributing to organ transplant immunosuppressant drug market growth. However, the low availability of organs and the high cost of overall transplantation procedure may hamper the market growth.
Based on drug class, the global organ transplant immunosuppressant drugs market is bifurcated into antibodies, steroids, mTOR inhibitor, antiproliferative agents, and calcineurin inhibitors. Calcineurin inhibitors drug class segment held the largest market share in 2018 whereas the antibodies segment is expected to exhibit the highest CAGR over the forecast period. Calcineurin inhibitors drug class includes majorly two drugs cyclosporine and tacrolimus. These effective drugs have widely been used for almost 20 years.
Based on transplant type global organ transplant immunosuppressant drugs market is bifurcated into pancreas, lung, heart, liver, kidney, and other. The kidney transplant was the most common transplant type across the globe in 2018. This is attributed to the comparatively easy availability of donor organs compared to other organs. Also, kidney transplant is more cost-effective as compared to prolonged periods of dialysis.
Based on the distribution channel global organ transplant immunosuppressant drugs market is segmented into retail pharmacies, online pharmacies, and hospital pharmacies. Hospital pharmacies held a leading market share in 2018 since it is the most widely preferred channel of distribution.
North America represents a developed regional market for organ transplant immunosuppressant drugs. The presence of favorable reimbursement policies, the presence of developed healthcare facilities, technological advancements, increasing healthcare spending is major factors driving the market growth in this region. Europe was the second-largest market in 2020. Asia Pacific is projected to witness rapid CAGR for organ transplant immunosuppressant drugs market. A dense population base, increasing chronic disease burden, increasing healthcare expenditure, the introduction of favorable reimbursement policies is expected to boost the market growth in the Asia Pacific. Latin America is will register noticeable growth over the forecast period. The Middle East and Africa will register sluggish growth in the years to come as a result of a lack of advanced healthcare infrastructure.
Major players included in the report are Bristol-Myers Squibb Company, Veloxis Pharmaceuticals A/S, GlaxoSmithKline plc, Dr. Reddys Laboratories Ltd., F. Hoffmann-La Roche Ltd., Mylan Laboratories, Inc., Novartis AG, Accord Healthcare Ltd., Sanofi Genzyme, and Astellas Pharma, Inc. among others.
In October 2020, GlaxoSmithKline (Ireland) Limited received marketing authorization valid throughout the European Union for Idefirix which is a medicine used to prevent the body from rejecting a newly transplanted kidney.
Idefirix is used before transplantation in adults who have antibodies against the donors kidney and are considered highly sensitized based on a positive crossmatch test. It should be reserved for patients who are unlikely to obtain a transplant under the available kidney allocation system.
Antibodies against the donors graft are a major obstacle to successful transplantation in patients with kidney failure. Patients who are highly sensitized therefore usually remain on dialysis with shorter life expectancy and poor quality of life. In light of this unmet medical need and despite the need for further data, the Agency considered that the available evidence suggests that Idefirix is effective at reducing antibody levels in highly sensitized adults, allowing them to receive a kidney transplant. The safety profile of Idefirix is considered manageable.
Idefirix has been given ˜conditional authorization. This means that there is more evidence to come about the medicine, which the company is required to provide. Every year, the Agency will review any new information that becomes available and this overview will be updated as necessary.
Graft organ rejection following solid organ transplantation is rare, and Idefirix was designated an ˜orphan medicine (a medicine used in rare diseases) on 12 January 2017. Idefirix contains the active substance imlifidase.
The report segment of the Global Organ transplant immunosuppressant drugs market as follows:
- Calcineurin Inhibitors
- Antiproliferative Agents
- mTOR Inhibitor
Global Organ Transplant Immunosuppressant Drugs Market: By Transplant Type
Global Organ Transplant Immunosuppressant Drugs Market: By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Organ Transplant Immunosuppressant Drugs Market: By Region
- The UK
- Rest of Europe
- South Korea
- Southeast Asia
- Rest of Asia Pacific
- Rest of Latin America
Middle East & Africa
- South Africa
- Rest of Middle East & Africa